Clinical trial
ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With…
NCT00261313 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00261313 |
|---|---|
| Title | ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer |
| Official title | An Open Label Phase 2 Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel Delivered Every 14 Days With Pegfilgrastim and Darbepoetin Alfa Support for the Adjuvant Treatment of Women With Breast Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Neulasta, Aranesp |
| Enrollment | 80 |
| Start date | Dec 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Dec 5, 2005 |
| Last update posted | Feb 26, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: